Journal article

Genetic comorbidity between major depression and cardio-metabolic traits, stratified by age at onset of major depression

Saskia P Hagenaars, Jonathan R Coleman, Shing Wan Choi, Helena Gaspar, Mark J Adams, David M Howard, Karen Hodgson, Matthew Traylor, Tracy M Air, Till FM Andlauer, Volker Arolt, Bernhard T Baune, Elisabeth B Binder, Douglas HR Blackwood, Dorret Boomsma, Archie Campbell, Micah Cearns, Darina Czamara, Udo Dannlowski, Katharina Domschke Show all

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics | WILEY | Published : 2020

Abstract

It is imperative to understand the specific and shared etiologies of major depression and cardio-metabolic disease, as both traits are frequently comorbid and each represents a major burden to society. This study examined whether there is a genetic association between major depression and cardio-metabolic traits and if this association is stratified by age at onset for major depression. Polygenic risk scores analysis and linkage disequilibrium score regression was performed to examine whether differences in shared genetic etiology exist between depression case control status (N cases = 40,940, N controls = 67,532), earlier (N = 15,844), and later onset depression (N = 15,800) with body mass ..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Medical Research Council


Awarded by US National Institute of Drug Abuse


Awarded by GSTT Charity


Awarded by Maudsley Charity


Awarded by Chief Scientist Office of the Scottish Government Health Directorates


Awarded by Scottish Funding Council


Awarded by Wellcome Trust


Awarded by NHMRC, Australia


Awarded by KNAW Academy Professor Award, Netherlands


Awarded by Vetenskapsradet, Sweden


Awarded by European Union, UK


Funding Acknowledgements

S. P. H. is funded by the Medical Research Council (MR/S0151132). CML is funding by the Medical Research Council (N015746/1). This study presents independent research supported by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. We thank participants and scientists involved in making the UK Biobank resource available (http://www.ukbiobank.ac.uk/).UK Biobank data used in this study were obtained under approved application 16577. We are deeply indebted to the investigators who comprise the PGC, and to the hundreds of thousands of subjects who have shared their life experiences with PGC investigators. The PGC has received major funding from the US National Institute of Mental Health and the US National Institute of Drug Abuse (U01 MH109528 and U01 MH1095320). Statistical analyses were carried out on the NL Genetic Cluster Computer (http://www.geneticcluster.org/) hosted by SURFsara, and the King's Health Partners High Performance Compute Cluster funded with capital equipment grants from the GSTT Charity (TR130505) and Maudsley Charity (980). We would like to thank the research participants and employees of 23andMe for making this work possible. Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award "STratifying Resilience and Depression Longitudinally" [STRADL] Reference 104036/Z/14/Z). Ethics approval for the Generation Scotland was given by the NHS Tayside committee on research ethics (reference 15/ES/0040), and all participants provided written informed consent for the use of their data. The MEGASTROKE project received funding from sources specified at http://www.megastroke.org/acknowledgments.html.CM Lewis is a member of Myriad Neuroscience SAB. PF Sullivan is on the scientific advisory board for Pfizer, Inc., and the advisory committee for Lundbeck. All other authors reported no biomedical financial interest or potential conflicts of interest. The table below lists the funding that supported the primary studies analyzed in this article. In addition, PGC investigators received personal funding from the following sources. NR Wray award 1078901, 1087889, and 1113400, NHMRC, Australia. DI Boomsma award PAH/6635, KNAW Academy Professor Award, Netherlands. PF Sullivan award D0886501, Vetenskapsradet, Sweden. AM McIntosh award 602450, European Union, UK; award BADiPS, NC3Rs, UK. C Hayward, Core funding, Medical Research Council, UK.